Earlier this week, President Donald Trump made a speech in New Hampshire to discuss the administration’s efforts in combatting both the opioid crisis and high drug prices. In the speech, Trump alluded to a possible press conference in the near future that would discuss potential proposals in reducing prescription drug prices.
Earlier this week, President Donald Trump made a speech in New Hampshire to discuss the administration’s efforts in combatting both the opioid crisis and high drug prices. In the speech, Trump alluded to a possible press conference in the near future that would discuss potential proposals in reducing prescription drug prices.
“We’re making medically assisted treatment more available and affordable, and we continue to increase competition and drive down drug prices…We’re going to have a major news conference, probably at the White House, in about a month, because all of you people — and I’m talking about prescription drugs, not necessarily the drugs that we’re talking about here. But we pay, as a country, so much for drugs because of the drug lobbies and other reasons, and the complexity of distribution, which is basically another term for saying, ‘How do we get more money?’” said Trump.
Drug pricing has gotten a lot of attention as of late, most recently with 9 physician groups voicing their opposition to Medicare drug pricing proposals in a joint letter sent to HHS.
Joining Trump in the conference was HHS Secretary Alex Azar, who spoke specifically about his department's efforts to bring drug prices down.
“Last year, the FDA approved more generic drugs than it ever has in its history,” said Azar. “And that brings prices down for patients, for the system, for everybody.”
However, some lawmakers have questioned Azar’s commitment to reducing drug prices. During Azar’s confirmation hearing, Kaiser Health News reported that Democrats, including Senator Ron Wyden, D-Oregon, pointed out that under Azar’s leadership, his previous company, drug maker Eli Lilly, had never authorized a decrease in a drug’s price during his tenure.
Azar also spoke to the same potential press conference that Trump had mentioned, stating that in about a month HHS will be “rolling out a whole slate of other proposals” around how drug prices are reduced and “how we bring discounts that the middlemen right now are getting; how those will go to our patients, to individuals,” said Azar.
The United States’ drug prices are among the highest in the world. “In some cases, it’s many times higher for the exact same pill…in the exact same package, made in the exact same plant. And we’re going to change that,” said Trump.
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.